期刊
ALLERGY
卷 77, 期 6, 页码 1667-1684出版社
WILEY
DOI: 10.1111/all.15203
关键词
allergic asthma; allergy diagnosis; bronchial allergen challenge; house dust mites
Allergic asthma is a common asthma phenotype that requires IgE sensitization to aeroallergens for diagnosis. However, current protocols for bronchial allergen challenge are not suitable for moderate-to-severe asthmatics or clinical practice. Correct diagnosis of allergic asthma can aid in selecting patients for immunomodulatory therapies, such as allergen sublingual immunotherapy.
Allergic asthma (AA) is a common asthma phenotype, and its diagnosis requires both the demonstration of IgE-sensitization to aeroallergens and the causative role of this sensitization as a major driver of asthma symptoms. Therefore, a bronchial allergen challenge (BAC) would be occasionally required to identify AA patients among atopic asthmatics. Nevertheless, BAC is usually considered a research tool only, with existing protocols being tailored to mild asthmatics and research needs (eg long washout period for inhaled corticosteroids). Consequently, existing BAC protocols are not designed to be performed in moderate-to-severe asthmatics or in clinical practice. The correct diagnosis of AA might help select patients for immunomodulatory therapies. Allergen sublingual immunotherapy is now registered and recommended for controlled or partially controlled patients with house dust mite-driven AA and with FEV1 >= 70%. Allergen avoidance is costly and difficult to implement for the management of AA, so the proper selection of patients is also beneficial. In this position paper, the EAACI Task Force proposes a methodology for clinical BAC that would need to be validated in future studies. The clinical implementation of BAC could ultimately translate into a better phenotyping of asthmatics in real life, and into a more accurate selection of patients for long-term and costly management pathways.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据